The Limited Times

Now you can see non-English news...

Corona vaccine from Johnson & Johnson: Germany will get ten million doses by the end of June

2021-03-29T15:34:53.886Z


Germany will receive the first corona vaccine from the US pharmaceutical giant Johnson & Johnson in mid-April. As SPIEGEL confirmed, 2.3 million cans will follow in May, and another 7.1 million in June.


Enlarge image

Johnson & Johnson vaccine

Photo: Cheryl Gerber / AP

The first deliveries of the fourth approved corona vaccine from Johnson & Johnson for Germany will come in mid-April.

256,800 cans are expected in the week of April 12th and another 444,000 cans in the week of April 26th.

That was confirmed to SPIEGEL from informed circles.

The "Bild" newspaper reported on it first.

2.3 million cans are to follow in May and 7.1 million in June, bringing together 10.1 million cans in the second quarter.

Accordingly, 22 million cans are expected in the third quarter, and another 4.6 million cans in the fourth quarter.

Johnson & Johnson's vaccine was approved in the European Union on March 11th.

A syringe is sufficient for the preparation, a second vaccination is not necessary.

The funds from Biontech / Pfizer, Moderna and Astrazeneca are already being used in Germany.

B

is for 400 million doses of vaccine for Africa

Johnson & Johnson also announced the delivery of up to 400 million vaccine doses to African countries.

"Nobody is safe before everyone is safe, and we are committed to fair, worldwide access to corona vaccines," said company boss Alex Gorsky.

The first deliveries of the vaccine are expected to arrive in the third quarter of this year.

The subsidiary Janssen Pharmaceutica has agreed with the African Vaccine Acquisition Trust (Avat) to deliver a total of 220 million doses.

Avat could order 180 million more cans.

According to the company, the J&J vaccine also protects against mutants of the coronavirus.

A worldwide study with almost 40,000 participants had shown an effectiveness of 85.4 percent against severe courses, the effectiveness for moderate courses was a good 66 percent.

In contrast to competing products, the vaccine does not need to be cooled as much, which makes transport and distribution easier.

ssu / dpa

Source: spiegel

All business articles on 2021-03-29

You may like

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.